Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX

被引:79
作者
Shitara, Kohei [1 ]
Matsuo, Keitaro [2 ]
Takahari, Daisuke [1 ]
Yokota, Tomoya [1 ]
Inaba, Yoshitaka [3 ]
Yamaura, Hidekazu [3 ]
Sato, Yozo [3 ]
Najima, Mina [3 ]
Ura, Takashi [1 ]
Muro, Kei [1 ]
机构
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Chikusa Ku, Aichi 4648681, Japan
[2] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Aichi, Japan
[3] Aichi Canc Ctr Hosp, Dept Diagnost & Intervent Radiol, Aichi 4648681, Japan
关键词
Colorectal cancer; Chemotherapy; FOLFOX; Neutropaenia; Prognostic factor; EFFICACY; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN;
D O I
10.1016/j.ejca.2009.01.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We retrospectively analysed 153 patients with metastatic colorectal cancer who received FOLFOX with or without bevacizumab as first-line chemotherapy. Several background characteristics and chemotherapy features (grade of neutropaenia, use of bevacizumab or irinotecan, re-introduction of FOLFOX, and tumour progression) as time-varying covariates were analysed as potential prognostic factors. Of the 153 patients, mild neutropaenia (grade 1-2) occurred in 60 patients (39%) and severe neutropaenia (grade 3-4) occurred in 46 patients (30%). The other 47 patients (31%) did not experience neutropaenia. According to a multivariate Cox model with time-varying covariates, hazard ratios (HRs) of death were 0.55 (95% confidence interval (CI), 0.31-0.98; P = 0.044) for patients with mild neutropaenia and 0.35 (95% Cl, 0.18-0.66; P = 0.002) for those with severe neutropaenia. Both mild and severe neutropaenia during chemotherapy are associated with improved survival in patients with MCRC. Prospective trials are required to assess whether dosing adjustments based on neutropaenia may improve chemotherapy efficacy. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1757 / 1763
页数:7
相关论文
共 50 条
[21]   A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer [J].
Boccia, Ralph V. ;
Cosgriff, Thomas M. ;
Headley, David L. ;
Badarinath, Suprith ;
Dakhil, Shaker R. .
CLINICAL COLORECTAL CANCER, 2010, 9 (02) :102-107
[22]   Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal Cancer [J].
Yamamoto, Seiji ;
Fujii, Hironori ;
Murayama, Kotaro ;
Iihara, Hirotoshi ;
Watanabe, Daichi ;
Yamada, Yunami ;
Kobayashi, Ryo ;
Kiyama, Shigeru ;
Makiyama, Akitaka ;
Urano, Kimihiko ;
Matsuhashi, Nobuhisa ;
Matsuura, Katsuhiko ;
Suzuki, Akio .
ANTICANCER RESEARCH, 2023, 43 (11) :5099-5105
[23]   Clinical and Economic Evaluation of First-line Therapy with FOLFIRI or Modified FOLFOX6 for Metastatic Colorectal Cancer [J].
Ajima, Hidetomo ;
Ogata, Hiroyasu ;
Fujita, Ken-ichi ;
Miwa, Keisuke ;
Sunakawa, Yu ;
Mizuno, Keiko ;
Ishida, Hiroo ;
Yamashita, Keishi ;
Nakayama, Hirofumi ;
Kawara, Kaori ;
Takahashi, Harumi ;
Sasaki, Yasutsuna .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (07) :634-638
[24]   Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study [J].
Van Cutsem, E. ;
Rivera, F. ;
Berry, S. ;
Kretzschmar, A. ;
Michael, M. ;
DiBartolomeo, M. ;
Mazier, M. -A. ;
Canon, J. -L. ;
Georgoulias, V. ;
Peeters, M. ;
Bridgewater, J. ;
Cunningham, D. .
ANNALS OF ONCOLOGY, 2009, 20 (11) :1842-1847
[25]   Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study [J].
Moscetti, Luca ;
Nelli, Fabrizio ;
Fabbri, Maria A. ;
Sperduti, Isabella ;
Alesini, Daniele ;
Cortesi, Enrico ;
Gemma, Donatello ;
Gamucci, Teresa ;
Grande, Roberta ;
Pavese, Ida ;
Franco, Daniela ;
Ruggeri, Enzo M. .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) :1035-1043
[26]   Retrospective Study as First-Line Chemotherapy Combined Anti-VEGF Antibody with Fluoropyrimidine for Frail Patients with Unresectable or Metastatic Colorectal Cancer [J].
Yoshida, Motoki ;
Goto, Masahiro ;
Kii, Takayuki ;
Nishitani, Hitoshi ;
Kawabe, Shinichiro ;
Kuwakado, Shin ;
Asaishi, Ken ;
Miyamoto, Takahiro ;
Higuchi, Kazuhide .
DIGESTION, 2013, 87 (01) :59-64
[27]   A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer [J].
Bendell, Johanna C. ;
Joseph, Mathew ;
Barnes, Kirk ;
Mainwaring, Mark ;
Shipley, Dianna ;
Reddy, Chandra ;
Blakely, Laura ;
Blachly, Ronald ;
Lane, Cassie M. ;
Earwood, Chris ;
Kuzur, Michel .
CANCER INVESTIGATION, 2017, 35 (06) :386-392
[28]   First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer [J].
Varol, Umut ;
Dirican, Ahmet ;
Yildiz, Ibrahim ;
Oktay, Esin ;
Degirmenci, Mustafa ;
Alacacioglu, Ahmet ;
Barutca, Sabri ;
Karabulut, Bulent ;
Uslu, Ruchan .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (07) :3157-3161
[29]   Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab [J].
Malka, D. ;
Boige, V. ;
Jacques, N. ;
Vimond, N. ;
Adenis, A. ;
Boucher, E. ;
Pierga, J. Y. ;
Conroy, T. ;
Chauffert, B. ;
Francois, E. ;
Guichard, P. ;
Galais, M. P. ;
Cvitkovic, F. ;
Ducreux, M. ;
Farace, F. .
ANNALS OF ONCOLOGY, 2012, 23 (04) :919-U5
[30]   Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial [J].
Muro, Kei ;
Itabashi, Michio ;
Hashida, Hiroki ;
Masuishi, Toshiki ;
Bando, Hiroyuki ;
Denda, Tadamichi ;
Yamanaka, Takeharu ;
Ohashi, Yasuo ;
Sugihara, Kenichi .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (04) :339-346